Richard Klausner, Director at Juno Therapeutics, Inc. (JUNO), sold 72,000 shares at $44.72 ($3.2M) on 2017-12-21, disclosed to the SEC on 2017-12-22.
Open-market sale of $3.2M JUNO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.72 | 32,859 | $1.5M | 45.6% |
| 2 | $44.72 | 32,859 | $1.5M | 45.6% |
| 3 | $45.16 | 3,141 | $142K | 4.4% |
| 4 | $45.16 | 3,141 | $142K | 4.4% |
| Total | $44.76 avg | 72,000 | $3.2M | 100% |
| Filing → |
| LYEL | SELL | 2022-09-27 | $71K | — | Filing → |
| JUNO | SELL | 2018-01-09 | $1.2M | — | Filing → |
| JUNO | SELL | 2017-09-08 | $1.0M | — | Filing → |